SCYX Scynexis
- 1.600
- +0.090+5.96%
- 1.620
- +0.020+1.25%
Scynexis News
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $8
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $8
Promising Clinical and Financial Prospects for SCYNEXIS: A Comprehensive Buy Rating Analysis
Buy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal Pipeline
Analysts' Top Healthcare Picks: Cormedix (CRMD), SCYNEXIS (SCYX)
Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects
Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership
SCYNEXIS Analyst Ratings
Promising Antifungal Drug Developments Bolster Buy Rating for SCYNEXIS
Analysts Have Conflicting Sentiments on These Healthcare Companies: SCYNEXIS (SCYX) and Kymera Therapeutics (KYMR)
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Ocuphire Pharma (OCUP)
Ladenburg Thalmann Cuts SCYNEXIS Price Target to $7.50 From $15, Maintains Buy Rating
SCYNEXIS (SCYX) Receives a Buy From Ladenburg Thalmann & Co.
SCYNEXIS (SCYX) Receives a Buy From Maxim Group
Cantor Fitzgerald Reiterates Overweight on SCYNEXIS, Maintains $15 Price Target
SCYNEXIS Analyst Ratings
SCYNEXIS (SCYX) Receives a Buy From Ladenburg Thalmann & Co.
Maxim Group Sticks to Its Buy Rating for SCYNEXIS (SCYX)
Ladenburg Thalmann & Co. Sticks to Their Buy Rating for SCYNEXIS (SCYX)
Guggenheim Adjusts Price Target on SCYNEXIS to $9 From $8, Maintains Buy Rating
Analysis
Price Target
No Data
No Data